Polymorphic forms of olanzapine

• US 6,348,458 B1
• Filed: 03/31/2000
• Issued: 02/19/2002
• Est. Priority Date: 12/28/1999
• Status: Expired due to Fees

• Current Assignee: Cipla (EU) Limited
• Original Assignee: U & I Pharmaceuticals, Ltd.
• Inventors: Rao, Dharmaraj R., Kankan, Rajendra N., Hamied, Yusuf K.
• Primary Examiner(s): COLEMAN, BRENDA LIBBY
• Application Number:
  US09/540,749
• Time in Patent Office: 690 Days
• Field of Search: 514/220, 540/557
• US Class Current: 514/220
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

The invention provides three new polymorphic forms of 2-methyl-4-[4-methyl-1-piperazinyl]-10H-thieno[2,3b][1,5]benzodiazepine (Olanzapine) (Formula A), the process for preparing the new polymorphs and pharmaceutical compositions containing the polymorphs. The new polymorphic forms of olanzapine are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions.

Claims

1. A process for producing a polymorph of olanzapine comprising:

dissolving an initial polymorph of olanzapine in aqueous acidic solution;

wherein the aqueous acidic solution comprises an acid selected from the group consisting of organic and inorganic acids; and

precipitating a different polymorph of olanzapine by neutralization;

wherein neutralization is accomplished by the addition of an aqueous or alcoholic solution of a base.

2. The process according to claim 1, wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, acetic acid, formic acid, citric acid, fumaric acid and maleic acid.

3. The process according to claim 1, wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, acetic acid and formic acid.

4. The process according to claim 1, wherein the solution of the base is selected from the group consisting of aqueous sodium hydroxide, alcoholic sodium hydroxide, aqueous potassium hydroxide, alcoholic potassium hydroxide and aqueous ammonia.

5. The process according to claim 1, wherein the alcoholic solution of the base comprises an alcohol selected from a mono, di, or polyhydric alcohol.

6. The process according to claim 5, wherein the alcohol is methanol.

7. The process according to claim 1, further comprising the step of:

recovering said different polymorph of olanzapine containing less than 5% of the initial form of olanzapine and less than 1% of other impurities.

8. The process according to claim 1, wherein the initial polymorph of olanzapine is Form I or Form II olanzapine, wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings:

9. The process according to claim 1, wherein the different polymorph of olanzapine is Form III olanzapine having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

10. The process according to claim 1, wherein the different polymorph of olanzapine is Form IV olanzapine having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

11. The process according to claim 1, wherein the different polymorph of olanzapine is Form V olanzapine having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

12. The process according to claim 1, wherein the precipitation is conducted at a temperature between about 0°

C. and about 100°

C.

13. The process according to claim 1, wherein the precipitation is conducted at a temperature between about 0°

C. and about 35°

C.

14. The process according to claim 1, wherein the precipitation is conducted at a temperature between about 10°

C. and about 30°

C.

15. The process according to claim 1, wherein the precipitation comprises adjusting the pH to between about 6 and about 12.

16. The process according to claim 1, wherein the precipitation comprises adjusting the pH to between about 8 and about 11.

17. The process according to claim 1, wherein the acidic solution comprises from about 5% to about 50% acid.

18. The process according to claim 1, wherein the acidic solution is about 50% acetic acid and the basic solution is about 15% aqueous ammonia.

19. The process according to claim 1, wherein the acidic solution is about 38% formic acid and the basic solution is about 10% methanolic sodium hydroxide.

20. The process according to claim 1, wherein the acidic solution is about 10% hydrochloric acid and the basic solution is about 10% aqueous sodium hydroxide.

21. The process according to claim 1, wherein the acidic solution is about 43% acetic acid and the basic solution is about 25% aqueous ammonia.

22. The process according to claim 1, wherein the acidic solution is about 40% acetic acid and the basic solution is about 50% aqueous sodium hydroxide.

23. The process according to claim 1, wherein the acidic solution is about 20% formic acid and the basic solution is about 25% aqueous ammonia.

24. The process according to claim 1, wherein the acidic solution is about 33% acetic acid and the basic solution is about 50% aqueous ammonia.

25. The process according to claim 1, wherein the acidic solution is about 50% acetic acid and the basic solution is about 25% aqueous ammonia.

26. Form III olanzapine polymorph having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

27. The Form III olanzapine polymorph according to claim 26, further comprising the following x-ray powder diffraction pattern, wherein d represents the interplanar spacing and I/I₁ represents the typical relative intensities:

28. The Form III olanzapine polymorph according to claim 26, further characterized by having an infrared spectrum comprising absorbances at the following wavenumbers:

611

656

671

746

765

845

935

1369.

29. The Form III olanzapine polymorph according to claim 26, produced by the process of:

dissolving Form I or Form II olanzapine in 50% aqueous acetic acid, and

precipitating substantially pure Form III olanzapine with 15% aqueous ammonia;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

30. The Form III olanzapine polymorph according to claim 26, produced by the process of:

dissolving Form I or Form II olanzapine in about 33% aqueous acetic acid, and

precipitating substantially pure Form III olanzapine with about 50% aqueous ammonia;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

31. Form IV olanzapine polymorph having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

32. The Form IV olanzapine polymorph according to claim 31, further comprising the following x-ray powder diffraction pattern, wherein d represents the interplanar spacing and I/I₁ represents the typical relative intensities:

33. The Form IV olanzapine polymorph according to claim 31, further characterized by having an infrared spectrum comprising absorbances at the following wavenumbers:

604

661

758

904

931

1365

1456.

34. The Form IV olanzapine polymorph according to claim 31, produced by the process of:

dissolving Form I or Form II olanzapine in about 38% aqueous formic acid, and

precipitating substantially pure Form IV olanzapine using about 10% methanolic sodium hydroxide;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

35. The Form IV olanzapine polymorph according to claim 31, produced by the process of:

dissolving Form I or Form II olanzapine in about 43% aqueous acetic acid, and

precipitating substantially pure Form IV olanzapine using about 25% aqueous ammonia;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray diffraction pattern represented by the following interplanar spacings;

36. Form V olanzapine polymorph having a typical x-ray powder diffraction pattern comprising the following interplanar spacings:

37. The Form V olanzapine polymorph according to claim 36, further comprising the following x-ray powder diffraction pattern, wherein d represents the interplanar spacing and I/I₁ represents the typical relative intensities:

38. The Form V olanzapine polymorph according to claim 36, further characterized by having an infrared spectrum comprising absorbances at the following wavenumbers:

604

671

746

758

847

928

1357

1369.

39. The Form V olanzapine polymorph according to claim 36, produced by the process of:

dissolving Form I or Form II olanzapine in about 10% aqueous hydrochloric acid, and

precipitating substantially pure Form V olanzapine using about 10% aqueous sodium hydroxide;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

40. The Form V olanzapine polymorph according to claim 36, produced by the process of:

dissolving Form I or Form II olanzapine in about 40% acetic acid, and

precipitating substantially pure Form V olanzapine using about 50% aqueous sodium hydroxide;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

41. The Form V olanzapine polymorph according to claim 36, produced by the process of:

dissolving Form I or Form II olanzapine in about 20% aqueous formic acid, and

precipitating substantially pure Form V olanzapine using about 25% aqueous ammonia;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;

42. The Form V olanzapine polymorph according to claim 36, produced by the process of:

dissolving Form I or Form II olanzapine in about 50% aqueous acid, and

precipitating substantially pure Form V olanzapine using about 25% aqueous ammonia;

wherein Form I olanzapine is an olanzapine polymorph having a typical x-ray powder diffraction pattern represented by the following interplanar spacings;